

FOR OFFICIAL USE ONLY

ACCESS DB #
PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Kahsay Habk Examiner #: 78271 Date: 6/29/05
Art Unit: 1624 Phone Number: 2- Serial Number: 10/705,446
Location (Bldg/Room#): 5C-15 (Mailbox #): 5C-18 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): _____









Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information.
appropriate serial number.

sued patent numbers) along with the



Please search the following core structures
(pyridine fused to N-containing 5-membered ring)
X=C, W=N in formula II

A & B may form carbocycle; A & R², B & R² may form a ring

Please see
a Hatched
for more
info

STAFF USE ONLY

Searcher: _____

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: _____

Searcher Prep & Review Time: _____

Online Time: _____

Type of Search

____ NA Sequence (#)

____ AA Sequence (#)

____ Structure (#)

____ Bibliographic

____ Litigation

____ Fulltext

____ Other

Vendors and cost where applicable

____ STN _____ Dialog

____ Questel/Orbit _____ Lexis/Nexis

____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial _____ Oligomer _____ Score/Length

____ Interference _____ SPDI _____ Encode/Transl

____ Other (specify)

Application

Habte 10/705,446

07/20/2005

L5 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:247338 HCAPLUS
 DOCUMENT NUMBER: 134:280854
 ENTRY DATE: Entered STN: 06 Apr 2001
 TITLE: Preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors
 INVENTOR(S): Horvath, Raymond F.; Tran, Jennifer; De, Lombaert Stephane; Hodgetts, Kevin Julian; Carpino, Philip A.; Griffith, David A.
 PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer, Inc.; De Lombaert, Stephane
 SOURCE: PCT Int. Appl., 211 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 INT. PATENT CLASSIF.:
 MAIN: C07D487-04
 SECONDARY: A61K031-519; A61K031-437; A61K031-4365; A61K031-47; A61K031-44; A61P009-00; A61P025-00; C07D471-04; C07D473-34; C07D215-46; C07D213-73; C07D239-48; C07D471-14; C07D495-04; C07D475-08; G01N033-566; C07D487-04; C07D239-00; C07D209-00
 CLASSIFICATION: 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023389	A2	20010405	WO 2000-US26886	20000929
WO 2001023389	A3	20020510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2379640	AA	20010405	CA 2000-2379640	20000929
EP 1224187	A2	20020724	EP 2000-967133	20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6506762	B1	20030114	US 2000-676941	20000929
JP 2003510327	T2	20030318	JP 2001-526541	20000929
NZ 517575	A	20040430	NZ 2000-517575	20000929
BG 106508	A	20030228	BG 2002-106508	20020311
NO 2002001358	A	20020527	NO 2002-1358	20020319
ZA 2002002518	A	20030630	ZA 2002-2518	20020328
US 2003158197	A1	20030821	US 2002-291446	20021108
US 6696445	B2	20040224		
US 2004229870	A1	20041118	US 2003-705446	20031110 <--
PRIORITY APPLN. INFO.:			US 1999-156870P	P 19990930
			US 2000-676941	A3 20000929
			WO 2000-US26886	W 20000929

US 2002-291446

A3 20021108

PATENT CLASSIFICATION CODES:

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001023389	ICM	C07D487-04
	ICS	A61K031-519; A61K031-437; A61K031-4365; A61K031-47; A61K031-44; A61P009-00; A61P025-00; C07D471-04; C07D473-34; C07D215-46; C07D213-73; C07D239-48; C07D471-14; C07D495-04; C07D475-08; G01N033-566; C07D487-04; C07D239-00; C07D209-00
WO 2001023389	ECLA	C07D213/73F6; C07D215/46; C07D239/48B1; C07D471/04+221B+209B; C07D471/04+235B+221B; C07D471/04+249B+221B; C07D471/04+241B+221B; C07D471/14+221C+221B+209C; C07D471/14+239B+221C+209C; C07D473/34; C07D475/08; C07D487/04+239B+209B; C07D487/04+239B+231B; C07D487/04+239C+235C; C07D487/04+239C+209C; C07D487/04+251C+209C; C07D495/04+333B+239B; C07D495/04+333B+221B
US 6506762	NCL	514/259.400; 514/259.410; 514/263.200; 514/263.210; 514/263.220; 514/263.230; 514/263.400; 514/264.110; 514/265.100; 544/080.000; 544/236.000; 544/254.000; 544/256.000; 544/257.000; 544/262.000; 544/276.000; 544/277.000; 544/278.000; 544/279.000; 544/281.000; 544/282.000
	ECLA	C07D213/73F6; C07D215/46; C07D239/48B1; C07D471/04+221B+209B; C07D471/04+235B+221B; C07D471/04+241B+221B; C07D471/04+249B+221B; C07D471/14+221C+221B+209C; C07D471/14+239B+221C+209C; C07D473/34; C07D475/08; C07D487/04+239C+209C; C07D487/04+239C+235C; C07D487/04+239B+231B; C07D487/04+239B+209B; C07D487/04+251C+209C; C07D495/04+333B+221B; C07D495/04+333B+239B
US 2003158197	NCL	514/245.000; 544/196.000; 544/197.000; 544/198.000; 544/199.000; 544/208.000; 544/209.000; 544/210.000
	ECLA	C07D213/73F6; C07D473/34; C07D475/08; C07D487/04+239C+209C; C07D487/04+239C+235C; C07D487/04+239B+231B; C07D487/04+239B+209B; C07D487/04+251C+209C; C07D495/04+333B+221B; C07D495/04+333B+239B; C07D215/46; C07D239/48B1; C07D471/04+221B+209B; C07D471/04+235B+221B; C07D471/04+241B+221B; C07D471/04+249B+221B; C07D471/14+221C+221B+209C; C07D471/14+239B+221C+209C
US 2004229870	NCL	514/229.500; 514/246.000; 514/251.000; 514/262.100; 514/261.100; 514/263.300; 514/265.100; 544/063.000; 544/182.000; 544/254.000
	ECLA	C07D213/73F6; C07D215/46; C07D239/48B1; C07D471/04+221B+209B; C07D471/04+235B+221B; C07D471/04+241B+221B; C07D471/04+249B+221B; C07D471/14+221C+221B+209C; C07D471/14+239B+221C+209C; C07D473/34; C07D475/08; C07D487/04+239B+209B; C07D487/04+239B+231B; C07D487/04+239C+209C; C07D487/04+239C+235C; C07D487/04+251C+209C; C07D495/04+333B+221B; C07D495/04+333B+239B

<--

OTHER SOURCE(S):
GRAPHIC IMAGE:

MARPAT 134:280854

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

ABSTRACT:

The title compds. [I-III, etc.; X = N, CR14; W = S, O, NR15; Y = N, CR3; E, F, G = CR3, N; R1 = H, alkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; A = (un)substituted (CH₂)_m (wherein m = 1-3); A and B form a (un)substituted carbocycle; A and R2, or B and R2 form (un)substituted aminocarbocycle, aminoheterocycle; B = (un)substituted (CH₂)_n (n = 1-3); R3, R16 = H, alkyl, etc.; R4 = (un)substituted aryl, heteroaryl; R5 = (cycloalkyl)alkyl, alkenyl, etc.; R6 = H, alkyl, etc.] which are potent antagonists at the NPY1 receptor, and are useful in treating physiol. disorders associated with an excess of neuropeptide Y, including eating disorders, such as, for example, obesity and bulimia, and certain cardiovascular diseases, for example, hypertension, were prepared. E.g., a multi-step synthesis of IV was described. The compds. I showed Ki of 0.1 nM - 10 μM against NPY1 receptor binding.

SUPPL. TERM: heterocycle nitrogen contg alkylenediamino substituted prepn
neuropeptide Y1 inhibitor; antiobesity heterocycle nitrogen
contg alkylenediamino substituted prepn

INDEX TERM: Neuropeptide Y receptors
ROLE: BSU (Biological study, unclassified); MSC
(Miscellaneous); BIOL (Biological study)
(Y1; preparation of certain alkylene diamine-substituted
heterocycles as NPY1 receptor inhibitors)

INDEX TERM: Heterocyclic compounds
ROLE: BAC (Biological activity or effector, except adverse);
BSU (Biological study, unclassified); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(nitrogen; preparation of certain alkylene diamine-substituted
heterocycles as NPY1 receptor inhibitors)

INDEX TERM: Antiobesity agents
(preparation of certain alkylene diamine-substituted
heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 332140-74-6P 332140-75-7P 332140-76-8P 332140-82-6P
332140-83-7P 332140-84-8P 332140-85-9P 332140-86-0P
332140-87-1P 332140-88-2P 332140-89-3P 332140-90-6P
332140-91-7P 332140-92-8P 332140-93-9P 332140-94-0P
332140-95-1P 332140-96-2P 332140-97-3P
332140-98-4P 332140-99-5P 332141-00-1P
332141-01-2P 332141-02-3P 332141-03-4P
332141-04-5P 332141-05-6P
332141-06-7P 332141-07-8P 332141-08-9P
332141-09-0P 332141-10-3P 332141-11-4P 332141-12-5P
332141-13-6P 332141-14-7P 332141-15-8P 332141-17-0P
332141-18-1P 332141-19-2P 332141-20-5P 332141-21-6P
332141-22-7P 332141-23-8P 332141-24-9P 332141-25-0P
332141-26-1P 332141-27-2P 332141-28-3P
332141-29-4P 332141-30-7P
332141-31-8P 332141-32-9P 332141-33-0P
332141-34-1P 332141-35-2P 332141-36-3P
332141-37-4P 332141-38-5P
332141-39-6P 332141-40-9P 332141-41-0P
332141-42-1P 332141-43-2P 332141-44-3P
332141-45-4P 332141-46-5P
332141-47-6P 332141-48-7P 332141-49-8P
332141-50-1P 332141-51-2P 332141-52-3P

332141-53-4P 332141-54-5P
 332141-56-7P 332141-58-9P 332141-59-0P
 332141-60-3P 332141-61-4P 332141-62-5P 332141-63-6P
 332141-64-7P 332141-65-8P 332141-66-9P 332141-67-0P
 332141-68-1P 332141-69-2P 332141-70-5P 332141-71-6P
 332141-72-7P 332141-73-8P 332141-74-9P 332141-75-0P
 332141-76-1P 332141-77-2P 332141-78-3P
 332141-79-4P 332141-80-7P
 332141-81-8P 332141-83-0P 332141-85-2P
 332141-86-3P 332141-87-4P 332141-88-5P
 332141-89-6P 332141-90-9P
 332141-91-0P 332141-92-1P 332141-93-2P
 332141-94-3P 332141-95-4P 332141-96-5P
 332141-97-6P 332141-98-7P
 332141-99-8P 332142-00-4P 332142-01-5P
 332142-02-6P 332142-03-7P 332142-04-8P
 332142-05-9P 332142-06-0P
 332142-07-1P 332142-08-2P 332142-09-3P
 332142-10-6P 332142-11-7P 332142-12-8P
 332142-13-9P 332142-14-0P
 332142-15-1P 332142-16-2P 332142-17-3P
 332142-18-4P 332142-19-5P 332142-20-8P
 332142-21-9P 332142-22-0P
 332142-23-1P 332142-24-2P 332142-25-3P
 332142-26-4P 332142-27-5P 332142-28-6P 332142-29-7P
 332142-30-0P 332142-31-1P 332142-32-2P 332142-33-3P
 332142-34-4P 332142-35-5P 332142-36-6P 332142-37-7P
 332142-38-8P 332142-39-9P 332142-40-2P 332142-41-3P
 332142-42-4P 332142-43-5P 332142-44-6P
 332142-45-7P 332142-46-8P
 332142-47-9P 332142-48-0P 332142-49-1P
 332142-50-4P 332142-51-5P 332142-52-6P
 332142-53-7P 332142-54-8P
 332142-55-9P 332142-56-0P 332142-57-1P
 332142-58-2P 332142-59-3P 332142-60-6P 332142-61-7P
 332142-62-8P 332142-63-9P 332142-64-0P 332142-65-1P
 332142-66-2P 332142-68-4P 332142-69-5P 332142-70-8P
 332142-71-9P 332142-72-0P 332142-73-1P 332142-74-2P
 332142-75-3P 332142-76-4P 332142-77-5P 332142-78-6P
 332142-79-7P 332142-80-0P 332142-81-1P 332142-82-2P
 332142-83-3P 332142-84-4P 332142-85-5P 332142-86-6P
 332142-87-7P 332142-88-8P 332142-89-9P 332142-90-2P
 332142-91-3P 332142-92-4P 332142-93-5P 332142-94-6P
 332142-95-7P 332142-96-8P 332142-97-9P 332142-98-0P
 332142-99-1P 332143-00-7P 332143-01-8P 332143-02-9P
 332143-03-0P 332143-04-1P 332143-05-2P 332143-06-3P
 332143-07-4P 332143-08-5P 332143-09-6P 332143-10-9P
 332143-11-0P 332143-12-1P 332143-13-2P 332143-14-3P
 332143-15-4P 332143-16-5P 332143-17-6P
 ROLE: BAC (Biological activity or effector, except adverse);
 BSU (Biological study, unclassified); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (preparation of certain alkylene diamine-substituted
 heterocycles as NPY1 receptor inhibitors)
 332143-18-7P 332143-19-8P 332143-20-1P 332143-21-2P
 332143-22-3P 332143-23-4P 332143-24-5P 332143-25-6P
 332890-16-1P 332890-18-3P 332890-19-4P

INDEX TERM:

332890-20-7P 332890-22-9P 332890-24-1P 332890-26-3P
 332890-28-5P 332890-30-9P 332890-32-1P
 332890-34-3P 332890-36-5P 332890-38-7P
 332890-40-1P 332890-42-3P 332890-43-4P
 332890-45-6P 332890-47-8P 332890-50-3P 332890-52-5P
 332890-54-7P 332890-56-9P 332890-58-1P
 332890-60-5P 332890-63-8P 332890-65-0P
 332890-67-2P 332890-68-3P 332890-70-7P
 332890-72-9P 332890-74-1P 332890-75-2P
 332890-76-3P 332890-78-5P 332890-80-9P 332890-81-0P
 332890-82-1P 332890-83-2P 332890-84-3P
 332890-86-5P 332890-87-6P 332890-89-8P 332890-91-2P
 332890-93-4P 332890-94-5P 332890-95-6P 332890-97-8P
 332890-99-0P 332891-01-7P 332891-03-9P 332891-05-1P
 332891-06-2P 332891-08-4P 332891-10-8P 332891-13-1P
 332891-15-3P

ROLE: BAC (Biological activity or effector, except adverse);
 BSU (Biological study, unclassified); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)

(preparation of certain alkylene diamine-substituted
 heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 77-76-9, 2,2-Dimethoxypropane 93-40-3,
 3,4-Dimethoxyphenylacetic acid 105-36-2, Ethyl
 bromoacetate 109-04-6, 2-Bromopyridine 120-13-8,
 2-(4-Ethoxy-3-methoxyphenyl)acetic acid 530-93-8,
 1,2,3,4-Tetrahydro-2-naphthalenone 34688-71-6,
 2-(2,4,6-Trimethylphenyl)ethanenitrile 204062-63-5
 332140-81-5

ROLE: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of certain alkylene diamine-substituted
 heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 252063-61-9P 252063-62-0P 252063-63-1P
 252063-64-2P 252063-65-3P 332140-77-9P 332140-78-0P
 332140-79-1P 332140-80-4P

ROLE: RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)
 (preparation of certain alkylene diamine-substituted
 heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 252063-66-4P

ROLE: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of certain alkylene diamine-substituted
 heterocycles as NPY1 receptor inhibitors)

INDEX TERM: 140110-45-8

ROLE: PRP (Properties)
 (unclaimed nucleotide sequence; preparation of certain
 alkylene diamine-substituted heterocycles as NPY1
 receptor inhibitors)

IT 332140-96-2P 332140-97-3P 332140-98-4P
 332140-99-5P 332141-04-5P 332141-05-6P
 332141-06-7P 332141-07-8P 332141-29-4P
 332141-30-7P 332141-31-8P 332141-32-9P
 332141-37-4P 332141-38-5P 332141-39-6P
 332141-40-9P 332141-45-4P 332141-46-5P
 332141-47-6P 332141-48-7P 332141-53-4P
 332141-54-5P 332141-56-7P 332141-58-9P
 332141-79-4P 332141-80-7P 332141-81-8P
 332141-83-0P 332141-89-6P 332141-90-9P


332141-91-0P 332141-92-1P 332141-97-6P
 332141-98-7P 332141-99-8P 332142-00-4P
 332142-05-9P 332142-06-0P 332142-07-1P
 332142-08-2P 332142-13-9P 332142-14-0P
 332142-15-1P 332142-16-2P 332142-21-9P
 332142-22-0P 332142-23-1P 332142-24-2P
 332142-45-7P 332142-46-8P 332142-47-9P
 332142-48-0P 332142-53-7P 332142-54-8P
 332142-55-9P 332142-56-0P 332890-16-1P
 332890-19-4P 332890-30-9P 332890-34-3P
 332890-38-7P 332890-42-3P 332890-54-7P
 332890-58-1P 332890-63-8P 332890-67-2P
 332890-70-7P 332890-74-1P 332890-82-1P
 332890-84-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)


RN 332140-96-2 HCAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)




RN 332140-97-3 HCAPLUS

CN 1,2-Ethanediamine, N-cyclohexyl-N'-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)




RN 332140-98-4 HCAPLUS
 CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332140-99-5 HCAPLUS

CN 1,2-Ethanediamine, N-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332141-04-5 HCAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332141-05-6 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)




RN 332141-06-7 HCAPLUS

CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332141-07-8 HCAPLUS
 CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332141-29-4 HCAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332141-30-7 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)




RN 332141-31-8 HCAPLUS

CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332141-32-9 HCAPLUS

CN 1,2-Ethanediamine, N-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332141-37-4 HCAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)



RN 332141-38-5 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)




RN 332141-39-6 HCAPLUS

CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332141-40-9 HCAPLUS
 CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332141-45-4 HCAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-46-5 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-47-6 HCAPLUS

CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332141-48-7 HCAPLUS
 CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332141-53-4 HCAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-54-5 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-56-7 HCAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332141-58-9 HCAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 332141-79-4 HCAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-80-7 HCAPLUS
 CN 1,2-Ethanediamine, N-cyclohexyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-
 2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-81-8 HCAPLUS
 CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[2,5-dimethyl-3-(
 2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX
 NAME)

PAGE 1-A




PAGE 2-A




RN 332141-83-0 HCAPLUS
 CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4;3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332141-89-6 HCAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-90-9 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-91-0 HCAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332141-92-1 HCAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332141-97-6 HCAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332141-98-7 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-99-8 HCAPLUS

CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332142-00-4 HCAPLUS
 CN 1,2-Ethanediamine, N-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332142-05-9 HCAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332142-06-0 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332142-07-1 HCAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332142-08-2 HCAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332142-13-9 HCAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332142-14-0 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332142-15-1 HCAPLUS

CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332142-16-2 HCAPLUS
 CN 1,2-Ethanediamine, N-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332142-21-9 HCAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 332142-22-0 HCAPLUS


CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332142-23-1 HCAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332142-24-2 HCAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332142-45-7 HCAPLUS
 CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-(cyclopentylamino)ethyl]amino]-1,3-dihydro-1,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9Cl) (CA INDEX NAME)



RN 332142-46-8 HCAPLUS


CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-(cyclohexylamino)ethyl]amino]-1,3-dihydro-1,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 332142-47-9 HCAPLUS

CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]ethyl]amino]-1,3-dihydro-1,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332142-48-0 HCAPLUS

CN 2H-imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1,5-dimethyl-7-[[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]ethyl]amino]-3-(2,4,6-trimethylphenyl)-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332142-53-7 HCAPLUS
 CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-(cyclopentylamino)ethyl]amino]-3-(2,6-dichloro-4-methoxyphenyl)-1,3-dihydro-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 332142-54-8 HCAPLUS


CN 2H-Imidazo[4,5-b]pyridin-2-one, 7-[[2-(cyclohexylamino)ethyl]amino]-3-(2,6-dichloro-4-methoxyphenyl)-1,3-dihydro-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 332142-55-9 HCAPLUS

CN 2H-Imidazo[4,5-b]pyridin-2-one, 3-(2,6-dichloro-4-methoxyphenyl)-7-[[2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]ethyl]amino]-1,3-dihydro-1,5-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332142-56-0 HCAPLUS
 CN 2H-Imidazo[4,5-b]pyridin-2-one, 3-(2,6-dichloro-4-methoxyphenyl)-1,3-dihydro-1,5-dimethyl-7-[[2-[[1-(2-pyrimidinyl)-4-piperidinyl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332890-16-1 HCAPLUS

CN 1,2-Ethanediamine, N-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)

D1-NH-CH₂-CH₂-NH


RN 332890-19-4 HCAPLUS

CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)

D1-NH-CH₂-CH₂-NH


RN 332890-30-9 HCAPLUS

CN 1,2-Ethanediamine, N-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



RN 332890-34-3 HCAPLUS

CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-3,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)




RN 332890-38-7 HCAPLUS

CN 1,2-Ethanediamine, N-[2,6-dimethyl-1-(2,4,6-trimethylphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



D1- NH-CH₂-CH₂-NH




RN 332890-42-3 HCAPLUS

CN 1,2-Ethanediamine, N-[1-(2,6-dichloro-4-methoxyphenyl)-2,6-dimethyl-3H-imidazo[4,5-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



D1- NH-CH₂-CH₂-NH




RN 332890-54-7 HCAPLUS

CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



D1- NH-CH₂-CH₂-NH




RN 332890-58-1 HCAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)




D1- NH-CH₂-CH₂-NH




RN 332890-63-8 HCAPLUS

CN 1,2-Ethanediamine, N-[1,5-dimethyl-3-(2,4,6-trimethoxyphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)




RN 332890-67-2 HCAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)




RN 332890-70-7 HCAPLUS

CN 1,2-Ethanediamine, N-[5-methyl-3-(2,4,6-trimethylphenyl)-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)

D1-NH-CH₂-CH₂-NH


RN 332890-74-1 HCAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-5-methyl-3H-1,2,3-triazolo[4,5-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)


D1-NH-CH₂-CH₂-NH

RN 332890-82-1 HCAPLUS

CN 2H-Imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-1,5-dimethyl-7-[[2-[(tetrahydro-2H-pyranyl)amino]ethyl]amino]-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

D1-NH-CH₂-CH₂-NH

RN 332890-84-3 HCAPLUS
 CN 2H-Imidazo[4,5-b]pyridin-2-one, 3-(2,6-dichloro-4-methoxyphenyl)-1,3-dihydro-1,5-dimethyl-7-[[2-[(tetrahydro-2H-pyranyl)amino]ethyl]amino]-(9CI) (CA INDEX NAME)



IT 252063-62-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)
 RN 252063-62-0 HCAPLUS
 CN 3-Indolizinecarboxylic acid, 2-amino-1-(2,4,6-trimethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)

